Who is sponsoring NCT00411957?

NCT00411957 is sponsored by The HIV Netherlands Australia Thailand Research Collaboration.

What condition does NCT00411957 study?

NCT00411957 studies HIV Infections.

What is the status of NCT00411957?

NCT00411957 is currently COMPLETED.

Last reviewed 2020-07-15 · How we verify

The Pharmacokinetics of Atazanavir / Ritonavir 200/100 OD Versus 300/100 mg OD in Combination With 2 NRTIs in HIV Pre-treated Patients

NCT00411957 Phase 1/Phase 2 COMPLETED

Several studies from HIV-NAT have demonstrated high nevirapine, indinavir, saquinavir and lopinavir/r levels when compared to Caucasian patients. Until now, the pharmacokinetics of atazanavir have not been explored in a Thai population. We postulate that ATV levels, as with other PIs, are higher in Thai people. Therefore, the level of ATV in ATV/RTV 300/100 OD may be higher than the acceptable range and could be associated with ATV related toxicity.

Details

Lead sponsor	The HIV Netherlands Australia Thailand Research Collaboration
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	22
Start date	2007-01
Completion	2008-01

Conditions

HIV Infections

Interventions

Atazanavir

Primary outcomes

the pharmacokinetics of atazanavir/ritonavir (ATV/RTV) 200/100 mg once daily in a sample of 22 patients experiencing virological success — 1 year

Countries

Thailand